| Literature DB >> 25359989 |
Ayline Kübler1, Jeanette Woiterski1, Kai-Erik Witte1, Hans-Jörg Bühring2, Udo F Hartwig3, Martin Ebinger1, Lena Oevermann4, Markus Mezger1, Wolfgang Herr5, Peter Lang1, Rupert Handgretinger1, Christian Münz6, Maya C André7.
Abstract
Therapeutic natural killer (NK)-cell-mediated alloreactivity toward acute myeloid leukemia has largely been attributed to mismatches between killer immunoglobulin-like receptors (KIRs) on NK cells and their ligands, HLA class I molecules, on target cells. While adult acute B-cell precursor leukemia (BCP-ALL) appears to be resistant to NK-cell-mediated lysis, recent data indicate that pediatric BCP-ALL might yet be a target of NK cells. In this study, we demonstrate in a donor-patient-specific NOD.Cg-Prkdc(scid) IL2rg(tmWjl)/Sz (NSG) xenotransplantation model that NK cells mediate considerable alloreactivity toward pediatric BCP-ALL in vivo. Notably, both adoptively transferred mature KIR(+) NK cells and immature KIR(-) NK cells arising early posttransplantation in humanized NSG mice exerted substantial antileukemic activity. Low-dose and long-term treatment of humanized NSG mice with the DNA-demethylating agent 5-aza-cytidine distinctly enhanced the antitumor response, interestingly without inducing common inhibitory KIR expression but rather by promoting the differentiation of various NK-cell precursor subsets. Collectively, these data indicate that the future design of innovative therapy protocols should consider further exploitation of NK-cell-mediated immune responses for poor prognosis pediatric BCP-ALL patients.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25359989 DOI: 10.1182/blood-2014-05-572743
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113